Want to see HALO full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently Halozyme runs and where it’s prioritizing investment.Halozyme’s cost base shifted from 2022 onward from modest R&D/SG&A to a lumpy, much-higher structure driven by big jumps in SG&A, cost of sales and the onset of recurring amortization—consistent with an acquisition or material licensing/commercialization activity that introduced amortizable intangibles and product COGS. R&D remains elevated but steadier, suggesting continued pipeline investment alongside commercialization costs. The large year-end 2025 spike looks like a discrete milestone/one-off step-up; investors should watch whether revenue growth meaningfully follows to avoid sustained margin and cash‑flow pressure.
Date | Research and Development | Selling, General, and Administrative | Amortization | Cost of Sales |
|---|---|---|---|---|
Jun 30, 2026 | $27.66M | $57.00M | $29.51M | $79.17M |
Mar 31, 2026 | $25.56M | $57.88M | $29.51M | $79.24M |
Dec 31, 2025 | $31.90M | $77.03M | $23.38M | $78.77M |
Sep 30, 2025 | $17.25M | $46.09M | $17.76M | $55.24M |
Jun 30, 2025 | $17.54M | $41.61M | $17.76M | $46.36M |
Mar 31, 2025 | $14.80M | $42.36M | $17.76M | $48.40M |
Dec 31, 2024 | $20.44M | $42.25M | $17.76M | $42.05M |
Sep 30, 2024 | $18.46M | $41.24M | $17.76M | $49.43M |
Jun 30, 2024 | $21.04M | $35.71M | $17.76M | $39.61M |
Mar 31, 2024 | $19.11M | $35.13M | $17.76M | $28.33M |